Cargando…
Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
The development of therapeutics to prevent or treat COVID-19 remains an area of intense focus. Protein biologics, including monoclonal antibodies and nanobodies that neutralize virus, have potential for the treatment of active disease. Here, we have used yeast display of a synthetic nanobody library...
Autores principales: | Pymm, Phillip, Redmond, Samuel J., Dolezal, Olan, Mordant, Francesca, Lopez, Ester, Cooney, James P., Davidson, Kathryn C., Haycroft, Ebene R., Tan, Chee Wah, Seneviratna, Rebecca, Grimley, Samantha L., Purcell, Damian F.J., Kent, Stephen J., Wheatley, Adam K., Wang, Lin-Fa, Leis, Andrew, Glukhova, Alisa, Pellegrini, Marc, Chung, Amy W., Subbarao, Kanta, Uldrich, Adam P., Tham, Wai-Hong, Godfrey, Dale I., Gherardin, Nicholas A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529347/ https://www.ncbi.nlm.nih.gov/pubmed/36213007 http://dx.doi.org/10.1016/j.isci.2022.105259 |
Ejemplares similares
-
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
por: Lopez, Ester, et al.
Publicado: (2021) -
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
por: Pymm, Phillip, et al.
Publicado: (2021) -
Heterologous SARS‐CoV‐2 IgA neutralising antibody responses in convalescent plasma
por: Davis, Samantha K, et al.
Publicado: (2022) -
Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
por: Haycroft, Ebene R., et al.
Publicado: (2023) -
An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)